Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.64 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.61 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.60 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.59 |
| ▸ | TLR2 | O60603 | 1/20 | 0.57 |
| ▸ | CASP2 | P42575 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14642513 | 0.96 | GLP1R (0.63) | GLP1RLPAR3NOD1LPAR1SIRT6 | |
| SCHEMBL18889446 | 0.94 | GLP1R (0.62) | GLP1RLPAR3NOD1LPAR1SIRT6 | |
| SCHEMBL18889580 | 0.94 | GLP1R (0.62) | GLP1RLPAR3NOD1LPAR1SIRT6 | |
| SCHEMBL22923736 | 0.93 | NAAA (0.63) | GLP1RLPAR3NOD1LPAR1SIRT6 | |
| SCHEMBL15369080 | 0.93 | GLP1R (0.61) | GLP1RLPAR3NOD1LPAR1SIRT6 | |
| SCHEMBL20542804 | 0.93 | LPAR3 (0.65) | GLP1RLPAR3NOD1LPAR1SIRT6 | |
| SCHEMBL20542805 | 0.93 | LPAR3 (0.65) | GLP1RLPAR3NOD1LPAR1SIRT6 | |
| SCHEMBL23443071 | 0.92 | GLP1R (0.60) | GLP1RLPAR3NOD1LPAR1SIRT6 | |
| SCHEMBL15720613 | 0.92 | SIRT6 (0.64) | GLP1RLPAR3NOD1LPAR1SIRT6 | |
| SCHEMBL2284037 | 0.92 | SIRT6 (0.64) | GLP1RLPAR3NOD1LPAR1SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | KIT, STRA6, HAVCR2 | GLP1R 2412/4885LPAR3 1024/4885NOD1 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.